The results of imatinib therapy for patients with primary eosinophilic disorders

Saved in:
Bibliographic Details
Published inEuropean journal of haematology Vol. 76; no. 6; pp. 535 - 536
Main Authors Helbig, Grzegorz, Stella-Holowiecka, Beata, Grosicki, Sebastian, Bober, Grazyna, Krawczyk, Magorzata, Wojnar, Jerzy, Reiter, Andreas, Hochhaus, Andreas, Holowiecki, Jerzy
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.06.2006
Subjects
Adult
Aged
Antineoplastic Agents - therapeutic use
Benzamides
Biomarkers, Tumor - analysis
Biomarkers, Tumor - genetics
Drug Evaluation
Eosinophilia - drug therapy
Female
Follow-Up Studies
Humans
Hypereosinophilic Syndrome - drug therapy
Hypereosinophilic Syndrome - genetics
Imatinib Mesylate
Male
Middle Aged
mRNA Cleavage and Polyadenylation Factors - analysis
mRNA Cleavage and Polyadenylation Factors - genetics
Myeloproliferative Disorders - drug therapy
Neoplasm Proteins - analysis
Neoplasm Proteins - genetics
Oncogene Proteins, Fusion - analysis
Oncogene Proteins, Fusion - genetics
Piperazines - therapeutic use
Protein Kinase Inhibitors - therapeutic use
Pyrimidines - therapeutic use
Receptor, Platelet-Derived Growth Factor alpha - analysis
Receptor, Platelet-Derived Growth Factor alpha - genetics
Treatment Outcome
Online AccessGet full text

Cover

More Information
Bibliography:istex:A7AF58A87276FFD9F3EDD4D69ECA7B007F8DB949
ArticleID:EJH652
ark:/67375/WNG-4H7G8RWN-8
SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0902-4441
1600-0609
DOI:10.1111/j.1600-0609.2006.00652.x